Glucagon in Beta Blocker Overdose: Application Scope Analysis
Title: Glucagon in Beta Blocker Overdose: Application Scope Analysis Abstract: Glucagon, a 29-amino acid peptide, is a critical antidote in beta blocker overdose (BBO) due to its non-receptor-mediated inotropic effect. Market data (2023–2030) project a 7.2% CAGR for therapeutic peptides, driven by BBO applications. Compared to catecholamines, glucagon offers superior chronotropic efficacy but limited stability (t½ 6 min). Key brands (GlucaGen® vs. generic) differ in reconstitution time and excipient profiles. Regulatory compliance (FDA/EMA) and cold-chain logistics (2–8°C) are essential for potency. Selection criteria prioritize purity (>95%) and endotoxin levels. Industry trends show increased demand for lyophilized formulations in emergency kits.